Lunch brief: Targeting glucose spikes with collagen peptides: New scientific and market research (Rousselot)

We are currently in the center of a revolution in our understanding of metabolism, where cutting-edge science and tech-driven innovation are coming together to support consumer health. With infinite knowledge at consumers’ fingertips, brands need to be prepared to focus on personalization, perceptions and behaviors. Case in point, the exponential use of glucose control devices, like continuous glucose monitors (CGM). Thanks in-part to these devices, consumers increasingly are becoming aware that our body’s capacity to maintain balanced glucose control is constantly being challenged by our modern lifestyle.

To address this concern, Rousselot developed Nextida GC, a specific collagen peptide composition that targets the glucose spike after a meal, as indicated in a first clinical study.

4 key takeaways include:

• An overview and understanding of the current metabolic health market evolution, key drivers, scientific trends and consumer behavior.
• Why delivering on efficacy is key.
• Case study: glucose control, market needs and consumer perceptions.
• Global launch of Nextida GC: a specific collagen peptide composition aiming to naturally reduce postprandial blood glucose spikes.

Speakers:

• Mariette Abrahams, Ph.D., founder and CEO, Qina
• Janne Prawitt, Ph.D., scientific director health & nutrition, Rousselot

This brief is an invite-only event. If you are interested in attending, please reach out to Shilo Lusson at shilo.lusson.us@informa.com.